Michael Wechsler, ERS 2020 – Dupilumab in the LIBERTY ASTHMA TRAVERSE Trial
We discuss with Michael Wechsler (National Jewish Health, Denver, CO, USA) the clinical evidence supporting the use of dupilumab in patients with asthma and specifically the major findings from the long-term safety evaluation of dupilumab in the LIBERTY ASTHMA TRAVERSE trial (NCT02134028).
Questions
1. What are the major unmet needs in the biologic treatment of moderate to severe asthma? (0:17)
2. Could you tell us a little about dupilumab, its mechanism of action and its advantages compared to other biologic therapies? (1:30)
3. What clinical evidence supports the efficacy and safety of dupilumab? (3:20)
4. Could you give us a brief overview of the LIBERTY ASTHMA TRAVERSE study and its major findings? (5:05)
5. Which patients are most likely to benefit from dupilumab therapy? (6:50)
Disclosures: Michael Wechsler has acted as a consultant for Sanofi Aventis, Regeneron, Amgen, AstraZeneca, Teva, GSK, Novartis, Genentech, Equillium, Cohero and Boehringer Ingelheim.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020.
